Fibrodysplasia ossificans progressiva (FOP) Pipeline Analysis report covers more than 5 companies currently in different phases of development. Fibrodysplasia ossificans progressiva (FOP) is a congenital connective tissue disorder where there is an abnormal development of the bone in areas where bones are not present. Hence, the heterotrophic ossification or ectopic ossification takes place in the areas of soft connective tissues (undergo metamorphosis) like tendons and ligaments and become rigid. Mobility becomes difficult or impossible. The disorder is caused by the mutations in ACVR1 gene or ALK2 gene. Symptoms show the malformations of the great toes, the first clinical symptom at the time of birth. The disorder is also known as stone man syndrome.
The report provides Fibrodysplasia ossificans progressiva (FOP) treatment drugs by company, phases of development including products in the early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Clementia Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc. among others.
Scope:
The report provides Fibrodysplasia ossificans progressiva (FOP) treatment drugs by company, phases of development including products in the early discovery stage and NDA filing, molecule type, route of administration and region. The report will help to evaluate the collaboration, in-licensing, and out-licensing opportunities, formulating business development strategies and tracking the activities of the key market players. Epidemiology, major drivers, restraints, and opportunities have been covered to provide an exhaustive picture of the market. The analysis presents in-depth information regarding the development, trends, and industry policies and regulations implemented to offer stakeholders a better understanding of the key factors affecting the overall market environment.
Various databases (for patents and Clinical Trials), studies and data published by industry associations, analyst reports, investor presentations, press releases and journals among others have been taken into consideration while conducting the secondary research.
Market intelligence is presented in the form of analysis, charts, and graphics to help the clients in gaining a faster and efficient understanding of the market.
Major industry players profiled as part of the report are Clementia Pharmaceuticals Inc. and Regeneron Pharmaceuticals, Inc. among others.
Scope:
- By Company
- By Phase
- By Molecule Type
- By Region
- By Route of Administration
Table of Contents
1. Introduction
2. Disease Overview
4. Market Dynamics
5. Pipeline Analysis/Outlook
6. Company profiling
Companies Mentioned
- Clementia
- Blueprint Medicines
- BIOCRYST PHARMACEUTICALS, INC.
- Regeneron
- Keros Therapeutics
- Oncodesign SA
- DAIICHI SANKYO COMPANY, LIMITED
- Novartis
Methodology
LOADING...
